CAPR Capricor Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CAPR

Price (delayed)

$5.47

Market cap

$171.76M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.83

Enterprise value

$159.3M

Capricor Therapeutics, Inc., is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases. Capricor's lead ...

Highlights
CAPR's equity has soared by 92% year-on-year
Capricor Therapeutics's gross profit has surged by 79% QoQ
CAPR's quick ratio has soared by 81% QoQ but it is down by 11% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://capricor.com
Peers: CYTK NBIX ABIO JNJ

Key stats

What are the main financial stats of CAPR
Market
Shares outstanding
31.4M
Market cap
$171.76M
Enterprise value
$159.3M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
7.45
Price to sales (P/S)
5.82
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.33
Earnings
Revenue
$25.18M
EBIT
-$22.29M
EBITDA
-$21.22M
Free cash flow
-$27.64M
Per share
EPS
-$0.83
Free cash flow per share
-$1.03
Book value per share
$0.73
Revenue per share
$0.94
TBVPS
$2.19
Balance sheet
Total assets
$58.73M
Total liabilities
$36.13M
Debt
$2.24M
Equity
$22.6M
Working capital
$19.59M
Liquidity
Debt to equity
0.1
Current ratio
1.63
Quick ratio
1.59
Net debt/EBITDA
0.59
Margins
EBITDA margin
-84.3%
Gross margin
100%
Net margin
-88.5%
Operating margin
-95.6%
Efficiency
Return on assets
-45.5%
Return on equity
-299.7%
Return on invested capital
-365%
Return on capital employed
-81.2%
Return on sales
-88.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CAPR stock price

How has the Capricor Therapeutics stock price performed over time
Intraday
4.39%
1 week
1.11%
1 month
-19.56%
1 year
42.45%
YTD
11.86%
QTD
-19.44%

Financial performance

How have Capricor Therapeutics's revenue and profit performed over time
Revenue
$25.18M
Gross profit
$25.18M
Operating income
-$24.08M
Net income
-$22.29M
Gross margin
100%
Net margin
-88.5%
The net margin has surged by 92% year-on-year and by 57% since the previous quarter
The company's operating margin has surged by 92% YoY and by 56% QoQ
Capricor Therapeutics's gross profit has surged by 79% QoQ
CAPR's revenue has surged by 79% since the previous quarter

Growth

What is Capricor Therapeutics's growth rate over time

Valuation

What is Capricor Therapeutics stock price valuation
P/E
N/A
P/B
7.45
P/S
5.82
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.33
The EPS rose by 30% year-on-year and by 28% since the previous quarter
CAPR's equity has soared by 92% year-on-year
CAPR's P/B is 8% higher than its 5-year quarterly average of 6.9
The price to sales (P/S) is 96% less than the 5-year quarterly average of 149.9 and 47% less than the last 4 quarters average of 10.9
CAPR's revenue has surged by 79% since the previous quarter

Efficiency

How efficient is Capricor Therapeutics business performance
CAPR's ROIC has plunged by 103% YoY but it is up by 10% from the previous quarter
The ROS has soared by 92% year-on-year and by 57% since the previous quarter
The ROE has shrunk by 82% YoY but it has soared by 51% QoQ
The ROA has increased by 27% QoQ and by 11% YoY

Dividends

What is CAPR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CAPR.

Financial health

How did Capricor Therapeutics financials performed over time
Capricor Therapeutics's total assets is 63% higher than its total liabilities
CAPR's quick ratio has soared by 81% QoQ but it is down by 11% YoY
The current ratio has surged by 81% since the previous quarter but it has declined by 10% year-on-year
The debt is 90% smaller than the equity
The debt to equity has soared by 107% from the previous quarter but it has plunged by 55% YoY
CAPR's equity has soared by 92% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.